| Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
| 2017 | Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients | Yeh, CN; Chang, YC; Su, Y; Hsu, DS; Cheng, CT; Wu, RC; Chung, YH; Chiang, KC; Yeh, TS; Lu, ML; Liu, CY; Chang, PM; Chen, MH; Huang, CY; Hsiao, M ; Chen, MH | Oncotarget 8(69), 113444-113459 | | | |
| 2020 | PRKDC: A New Biomarker and drug target for Checkpoint Blockade Immunotherapy | Tan, KT; Yeh, CN; Chang, YC; Cheng, JH; Fang, WL; Yeh, YC; Hsu, DS; Wu, CE; Liu, CY; Chang, MS; Lu, ML; Chen, SJ; Yee, C; Hsiao, M ; Chen, MH | Journal for ImmunoTherapy of Cancer 8(1), e000485 | | | |
| 2021 | Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway | Chung, SY; Hung, YP; Pan, YR; Chang, YC; Wu, CE; Hsu, DS; Chang, PM; Lu, ML; Huang, CY; Su, Y; Hsiao, M ; Yeh, CN; Chen, MH | BIOMEDICINES 9(8), 885 | | | |
